Insmed Inc (INSM) - Financial and Strategic SWOT Analysis Review

May 2021 | 52 pages | ID: I90BF56F9F8EN
GlobalData

Abstracts

Insmed Inc (INSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Insmed Inc (Insmed) is a biopharmaceutical company that focuses on developing novel therapeutics for rare diseases. Its marketed product: Arikayce (liposomal amikacin for inhalation) is indicated for mycobacterium avium complex (MAC) lung infection and NTM lung infections caused by MAC in adult patients. The company uses its proprietary, liposomal technology to develop its novel drug candidates. Its pipeline products include brensocatib, an orally administered reversible inhibitor of dipeptidyl peptidase 1 (DPP1) for treating non-cystic fibrosis (non-CF) bronchiectasis, cystic fibrosis and COVID-19; TPIP, an inhaled formulation of a treprostinil prodrug which is being developed for pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis, and PAH associated with interstitial lung diseases. The company through its subsidiaries operates in the US, the UK, the Netherlands, Ireland, Germany, France and Japan. Insmed is headquartered in Bridgewater, New Jersey, the US.

Insmed Inc Key Recent Developments

Feb 25,2021: Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Feb 12,2021: Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021
Oct 29,2020: Insmed reports third quarter 2020 financial results and provides business update
Sep 16,2020: Insmed to host R&D day on September 30, 2020
Aug 06,2020: Insmed reports second quarter 2020 financial results and provides business update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Insmed Inc - Key Facts
Insmed Inc - Key Employees
Insmed Inc - Key Employee Biographies
Insmed Inc - Major Products and Services
Insmed Inc - History
Insmed Inc - Company Statement
Insmed Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Insmed Inc - Business Description
R&D Overview
Insmed Inc - Corporate Strategy
Insmed Inc - SWOT Analysis
SWOT Analysis - Overview
Insmed Inc - Strengths
Insmed Inc - Weaknesses
Insmed Inc - Opportunities
Insmed Inc - Threats
Insmed Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Insmed Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 25, 2021: Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Feb 12, 2021: Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021
Oct 29, 2020: Insmed reports third quarter 2020 financial results and provides business update
Sep 16, 2020: Insmed to host R&D day on September 30, 2020
Aug 06, 2020: Insmed reports second quarter 2020 financial results and provides business update
Apr 30, 2020: Insmed reports first quarter 2020 financial results and provides business update
Apr 02, 2020: Insmed appoints Carol A. Schafer to its Board of Directors
Mar 16, 2020: Insmed Provides Business Update
Feb 25, 2020: Insmed reports fourth quarter and full year 2019 financial results and provides business update
Feb 25, 2020: Insmed to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, February 25, 2020

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Insmed Inc, Key Facts
Insmed Inc, Key Employees
Insmed Inc, Key Employee Biographies
Insmed Inc, Major Products and Services
Insmed Inc, History
Insmed Inc, Subsidiaries
Insmed Inc, Key Competitors
Insmed Inc, Ratios based on current share price
Insmed Inc, Annual Ratios
Insmed Inc, Annual Ratios (Cont...1)
Insmed Inc, Interim Ratios
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Insmed Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Insmed Inc, Performance Chart (2016 - 2020)
Insmed Inc, Ratio Charts
Insmed Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Insmed Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021